These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 25787278)

  • 1. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Qiu Z; Xiong S; He Y
    J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
    J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
    Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
    J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket.
    Chong H; Qiu Z; Su Y; Yang L; He Y
    AIDS; 2015 Jan; 29(1):13-21. PubMed ID: 25562490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket.
    Zhang X; Zhu Y; Hu H; Zhang S; Wang P; Chong H; He J; Wang X; He Y
    Front Cell Infect Microbiol; 2018; 8():51. PubMed ID: 29535974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.
    Chong H; Yao X; Qiu Z; Sun J; Qiao Y; Zhang M; Wang M; Cui S; He Y
    J Antimicrob Chemother; 2014 Oct; 69(10):2759-69. PubMed ID: 24908047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor.
    Wu X; Liu Z; Ding X; Yu D; Wei H; Qin B; Zhu Y; Chong H; Cui S; He Y
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29321334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
    Zhu Y; Ding X; Yu D; Chong H; He Y
    J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014).
    Zhang D; Li W; Jiang S
    Expert Opin Ther Pat; 2015 Feb; 25(2):159-73. PubMed ID: 25428639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
    Champagne K; Shishido A; Root MJ
    J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1.
    Chong H; Yao X; Qiu Z; Sun J; Zhang M; Waltersperger S; Wang M; Liu SL; Cui S; He Y
    FASEB J; 2013 Mar; 27(3):1203-13. PubMed ID: 23233535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
    Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
    Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile.
    Su S; Ma Z; Hua C; Li W; Lu L; Jiang S
    Molecules; 2017 Nov; 22(11):. PubMed ID: 29156603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
    Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
    J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions.
    Qi Q; Wang Q; Chen W; Du L; Dimitrov DS; Lu L; Jiang S
    Emerg Microbes Infect; 2017 Jun; 6(6):e59. PubMed ID: 28634358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.
    Izumi K; Kodama E; Shimura K; Sakagami Y; Watanabe K; Ito S; Watabe T; Terakawa Y; Nishikawa H; Sarafianos SG; Kitaura K; Oishi S; Fujii N; Matsuoka M
    J Biol Chem; 2009 Feb; 284(8):4914-20. PubMed ID: 19073606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
    Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.